Oncology News | pharmaphorum

News

AstraZeneca, C4XD sign exclusive $402 million global licence

C4X Discovery Holdings has signed an exclusive global licence worth up to $402 million with AstraZeneca (AZ) for the development and commercialisation of the NRF2 Activator programme.

News

Helsinki_University _Hospital_cancer_care

EU launches AI-powered real-world data project for cancer th...

The European Commission has provided around €7 million ($7.2 million) in funding to a new project that aims to boost the ability of hospitals within the EU to collect real-world data (RWD)

News

FDA rejects Spectrum's lung cancer drug poziotinib

The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor for a form of lung cancer, according to South Korea's Hanmi Pharma, which origi

News

Opdivo backed by NICE for rare gastro-oesophageal cancers

Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales.

News

Pharma M&A rumour mill grinds out Mirati's name again

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS

News

EC approves Regeneron's Libtayo for advanced cervical cancer

Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cer

AstraZeneca, C4XD sign exclusive $402 million global licence

EU launches AI-powered real-world data project for cancer th...

FDA rejects Spectrum's lung cancer drug poziotinib

Opdivo backed by NICE for rare gastro-oesophageal cancers

Pharma M&A rumour mill grinds out Mirati's name again

EC approves Regeneron's Libtayo for advanced cervical cancer

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks